12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PredicTOR diagnostic data

An exploratory study analyzing tumor samples surgically removed prior to treatment with Herceptin trastuzumab from 45 patients with HER2-positive breast cancer showed that 20/20 GeneSystems' PredicTOR test correctly identified 28 of 32 tumors that ultimately responded to Herceptin (87.5% sensitivity) and 10...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >